Safety and efficacy of combined clozapine–lithium pharmacotherapy
|Professorship/Faculty:||Professur für Pathopsychologie||Author(s):||Bender, Stefan; Linka, Thomas; Wolstein, Jörg ; Gehendges, Susanne; Paulus, Hermann-Josef; Schall, Ulrich; Gastpar, Markus||Pages / Size:||59-63||Title of the Journal:||The international journal of neuropsychopharmacology : official scientific journal of the Collegium Internationale Neuro-Psychopharmacologicum (CINP)||Language(s):||English||ISSN:||1461-1457|
|Volume:||7||Issue:||1||Publisher Information:||Univ. Press||Year of publication:||2004||Abstract:||
Several case reports described neurotoxic side-effects in the course of a combined clozapine-lithium treatment. Here we report on the safety and efficacy of this combination in a sample of 44 hospital patients. Medical records were retrospectively audited and a subsample of 23 patients was re-assessed. Mean total duration of combined treatment was 23.5 months. The combination (indications: prophylaxis; treatment of affective symptoms or aggression/excitement; augmentation of neuroleptic efficacy) was rated effective in 84% and adverse events were reported in 64% of the patients. Notably, most of the adverse events were benign and transient. However, 8 patients (18%) developed transient neurological adverse events that were genuinely novel in only 3 patients (7%) and coincided with high dosage of medication or high plasma levels or serotonergic (antidepressant) co-medication. Our data suggest that combined clozapine-lithium treatment may appear to be safe and effective when administered within a moderate therapeutic dose range and without serotonergic co-medication or other substances interfering with clozapine metabolism.
|DOI:||10.1017/S1461145703003870||Document Type:||Article||URI:||https://fis.uni-bamberg.de/handle/uniba/44667||Release date:||2. November 2018|
Items in DSpace are protected by copyright